BRPI0418122A - formulação farmacêutica de liberação controlada - Google Patents

formulação farmacêutica de liberação controlada

Info

Publication number
BRPI0418122A
BRPI0418122A BRPI0418122-0A BRPI0418122A BRPI0418122A BR PI0418122 A BRPI0418122 A BR PI0418122A BR PI0418122 A BRPI0418122 A BR PI0418122A BR PI0418122 A BRPI0418122 A BR PI0418122A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
controlled release
release pharmaceutical
dose
controlled
Prior art date
Application number
BRPI0418122-0A
Other languages
English (en)
Inventor
Polonca Kuhar
Sirca Judita
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0418122A publication Critical patent/BRPI0418122A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO FARMACêUTICA DE LIBERAçãO CONTROLADA". Na presente invenção, é descrita uma nova formulação farmacêutica com liberação controlada da substância ativa, em baixa dose, livremente solúvel em água usada para administração de no máximo uma vez ao dia. A substância ativa é mantida em uma concentração terapêutica adequada no sangue por pelo menos um período de 24 horas, independente do valor de pH fisiológico ao qual a formulação farmacêutica é exposta.
BRPI0418122-0A 2003-12-23 2004-12-22 formulação farmacêutica de liberação controlada BRPI0418122A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200300317A SI21637A (sl) 2003-12-23 2003-12-23 Farmacevtska oblika z nadzorovanim sproščanjem
PCT/SI2004/000044 WO2005060939A2 (en) 2003-12-23 2004-12-22 Controlled-release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BRPI0418122A true BRPI0418122A (pt) 2007-04-17

Family

ID=34709497

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418122-0A BRPI0418122A (pt) 2003-12-23 2004-12-22 formulação farmacêutica de liberação controlada

Country Status (12)

Country Link
US (1) US20070141149A1 (pt)
EP (1) EP1699439A2 (pt)
JP (1) JP2007516282A (pt)
CN (1) CN1897923A (pt)
AR (1) AR048138A1 (pt)
AU (1) AU2004305422B2 (pt)
BR (1) BRPI0418122A (pt)
CA (1) CA2547586C (pt)
RU (1) RU2447884C2 (pt)
SI (1) SI21637A (pt)
WO (1) WO2005060939A2 (pt)
ZA (1) ZA200603656B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006232696A (ja) * 2005-02-23 2006-09-07 Taisho Pharm Ind Ltd 徐放性製剤
JP5524624B2 (ja) * 2007-11-16 2014-06-18 旭化成ケミカルズ株式会社 水系フィルムコーティング液、および、フィルムコーティング顆粒、ならびに、これを用いた錠剤
CA2741041C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
WO2023072872A1 (en) 2021-10-25 2023-05-04 Farmalíder, S.A. Tadalafil oral suspension
CN115300506A (zh) * 2022-08-11 2022-11-08 南京红地生物科技有限公司 含有坦索罗辛和米拉贝隆的复方制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5041430A (en) * 1989-09-18 1991-08-20 Du Pont Mereck Pharmaceutical Company Oral anticoagulant/platelet inhibitor low dose formulation
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
AU8604098A (en) * 1997-08-01 1999-02-22 Acushnet Company Golf ball and method of making same
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
AU2001239841B2 (en) * 2000-02-24 2006-04-27 Shionogi, Inc. Antibiotic and antifungal compositions
US6610328B2 (en) * 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
PL361452A1 (en) * 2001-07-27 2004-10-04 Yamanouchi Pharmaceutical Co.Ltd. Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
EP1575639A2 (en) * 2002-01-04 2005-09-21 Ivax Research, Inc. Drug delivery system for sustained delivery of glipizide
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
CN1897923A (zh) 2007-01-17
JP2007516282A (ja) 2007-06-21
ZA200603656B (en) 2007-09-26
AU2004305422A1 (en) 2005-07-07
EP1699439A2 (en) 2006-09-13
SI21637A (sl) 2005-06-30
US20070141149A1 (en) 2007-06-21
AU2004305422B2 (en) 2010-12-23
WO2005060939A2 (en) 2005-07-07
WO2005060939A3 (en) 2005-12-29
RU2447884C2 (ru) 2012-04-20
AR048138A1 (es) 2006-04-05
RU2006126786A (ru) 2008-01-27
CA2547586C (en) 2012-12-04
CA2547586A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
Mendel et al. Therapy with hyperbaric oxygen and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats
BR0015284A (pt) Formulações de hidrocodona de liberação controlada
NO20055880L (no) Memantin orale doseringsformer
WO2004112711A3 (en) Oral extended-release composition
MXPA02012793A (es) Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
BRPI0418122A (pt) formulação farmacêutica de liberação controlada
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
BR0115390A (pt) Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
BR0315659A (pt) Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
EP0521057A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL USES OF THESE COMPOSITIONS.
MD2211G2 (ro) Remediu pentru tratamentul afecţiunilor periodonţiului
BRPI0417796A (pt) preparado efervescente de uma substáncia básica de efeito medicinal
TW200626133A (en) Oral medication for twice-daily administration
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
Rozman et al. Topical idoxuridine in the treatment of genital herpes
BR0211734A (pt) Derivados do ácido 5,6,6a,11b-tetraidro- 7-oxa-5-aza- benzo [c] fluoreno-6-carboxìlico substituìdos como antagonistas do nmda

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.